Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine

• Zhaojin Yu,
• Wensi Liu,
• Ying He,
• Mingli Sun,
• Jiankun Yu,
• Xue Jiao,
• Qiang Han,
• Haichao Tang,
• Bing Zhang,
• Yunkai Xian,
• Jing Qi,
• Jing Gong,
• Wang Xin,
• Gang Shi,
• Fengping Shan,
• Rui Zhang,
• Jianping Li,
• Minjie Wei

Affiliations

Zhaojin Yu

Department of Pharmacology, School of Pharmacy, China Medical University

Wensi Liu

Department of Pharmacology, School of Pharmacy, China Medical University

Ying He

Department of Pharmacology, School of Pharmacy, China Medical University

Mingli Sun

Department of Pharmacology, School of Pharmacy, China Medical University

Jiankun Yu

Department of Pharmacology, School of Pharmacy, China Medical University

Xue Jiao

Department of Pharmacology, School of Pharmacy, China Medical University

Qiang Han

Department of Pharmacology, School of Pharmacy, China Medical University

Haichao Tang

Department of Pharmacology, School of Pharmacy, China Medical University

Bing Zhang

Department of Pharmacology, School of Pharmacy, China Medical University

Yunkai Xian

Department of Pharmacology, School of Pharmacy, China Medical University

Jing Qi

Department of Pharmacology, School of Pharmacy, China Medical University

Jing Gong

Department of Pharmacology, School of Pharmacy, China Medical University

Wang Xin

Liaoning Medical Diagnosis and Treatment R&D Centre Co. Ltd.

Gang Shi

Department of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute

Fengping Shan

Department of Immunology, College of Basic Medical Science, China Medical University

Rui Zhang

Department of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute

Jianping Li

Department of Pharmacology, School of Pharmacy, China Medical University

Minjie Wei

Department of Pharmacology, School of Pharmacy, China Medical University